HCPCS code J2916: Billing guide for sodium ferric gluconate injection

Key Takeaways

HCPCS code J2916 describes Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg (brand name: Ferrlecit), billed per 12.5 mg increment.

A standard 125 mg dose requires 10 units of J2916 (125 mg divided by 12.5 mg per unit). Miscalculating units is a leading cause of claim denials and audit flags.

J2916 is subject to CMS JW and JZ modifier policy: report JW for discarded drug wastage and JZ when there is zero wastage. Omitting these modifiers risks claim rejection.

Pabau’s claims management software helps infusion clinics track drug units, attach required modifiers, and submit accurate J-code claims without manual calculation errors.

HCPCS code J2916: Definition, drug description, and clinical use

HCPCS code J2916 describes Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg, commonly known by its brand name Ferrlecit. Claims management software can automate the unit math, but billers still need a firm grasp of how J2916 works before they submit.

J2916 is a HCPCS Level II J-code, meaning it classifies drugs and biologicals administered by injection or infusion outside the oral route. It falls under the CMS HCPCS Level II category “Drugs Administered Other than Oral Method.” The code is active for 2026 with no changes to the billing unit structure.

Clinically, sodium ferric gluconate complex in sucrose is an intravenous iron replacement agent. Physicians prescribe it primarily for iron deficiency anemia (IDA) in patients who cannot absorb adequate oral iron, and for patients with chronic kidney disease (CKD) on hemodialysis who require iron supplementation to support erythropoiesis-stimulating agent (ESA) therapy, such as epoetin biosimilars billed under HCPCS code Q5105.

Quick reference: J2916 code properties

Billing units for HCPCS code J2916: How to calculate correctly

J2916 is billed per 12.5 mg of sodium ferric gluconate complex in sucrose. The math is straightforward, but billing the wrong number of units is one of the most common J-code errors flagged during Medicare audits.

To find your units, divide the total milligrams administered by 12.5. For IV therapy clinics administering a standard 125 mg dose (two 62.5 mg vials), that works out to exactly 10 units. A partial 62.5 mg dose bills as 5 units.

Common dose-to-unit conversions

Always document the exact milligrams administered in the patient’s clinical record before billing. Billed units that do not match documented administration create audit risk under the buy-and-bill model. Practices running multiple infusion sessions should review IV therapy EMR software that auto-calculates units from documented dose entries to reduce this exposure.

When a vial is opened but not fully used, the administered units and the wasted units must be reported separately. This is where JW and JZ modifiers come in (covered in the next section).

JW and JZ modifier requirements for HCPCS code J2916

CMS requires specific modifiers on J2916 claims to identify how drug from an opened vial was handled. Getting this wrong is a billing compliance risk, not just an administrative inconvenience.

Under the CMS JW/JZ Modifier Policy, J2916 appears on the official list of covered codes subject to this requirement. Here is how each modifier applies:

• JW modifier: Append to a separate line on the claim reporting the milligrams (and corresponding units) discarded from an opened vial. The administered dose and the wasted dose appear on separate lines. Example: a 125 mg vial opened, 100 mg administered (8 units, no modifier), 25 mg discarded (2 units, JW modifier).
• JZ modifier: Append to the administered line when there is zero drug wastage from the vial. This signals to the payer that the entire vial was used and no waste line is needed. Omitting JZ when waste is zero can trigger requests for additional documentation.

Both modifiers are mandatory on Medicare Part B claims for single-dose vial drugs like Ferrlecit. Many commercial payers have adopted the same policy, though requirements vary.

Clinics with IV therapy clinic workflows should build modifier logic into their claims process at the point of documentation, not at the billing stage, so the administered vs. discarded split is captured in real time.

Medicare reimbursement and ASP pricing for HCPCS code J2916

Medicare Part B reimburses physician-administered drugs like J2916 under the buy-and-bill model. The standard formula is ASP + 6%, where ASP is the Average Sales Price published quarterly by CMS.

CMS updates ASP pricing files each quarter, so reimbursement amounts change four times per year. Billers should verify current figures directly through the CMS Physician Fee Schedule lookup tool before submitting claims. The rate stated here reflects general methodology; confirm the current quarter’s ASP file for exact dollar amounts.

Two additional pricing benchmarks appear frequently in J2916 billing conversations:

• WAC (Wholesale Acquisition Cost): The manufacturer’s list price to wholesalers, before discounts. Medicare does not reimburse at WAC directly, but some commercial payers reference WAC in their contracts.
• AWP (Average Wholesale Price): A benchmark figure used by many state Medicaid programs and commercial payers, typically set as a percentage of AWP (e.g., AWP minus 15%). AWP-based reimbursement is common in older payer contracts.

For dialysis facilities, HCPCS code J2916 billing follows a different reimbursement pathway under the ESRD Prospective Payment System (PPS). In most cases, IV iron is bundled into the dialysis facility’s composite rate rather than billed separately with J2916.

Physician practices billing J2916 outside a dialysis setting (e.g., hospital outpatient or office infusion suite) will use the ASP+6% methodology under Part B. Clinics setting up IV therapy clinic billing workflows should clarify their place of service before assuming the Part B ASP rate applies.

Take the unit math out of J-code billing

Pabau's claims management tools help infusion clinics document administered doses, calculate J2916 units automatically, and attach JW/JZ modifiers at the point of care – so your billing team submits clean claims from day one.

Book a demo

ICD-10 diagnosis codes commonly paired with J2916

Every J2916 claim needs a supporting diagnosis code that establishes medical necessity. Payers will deny the claim if the listed diagnosis does not clinically justify intravenous iron administration.

The most frequently paired ICD-10-CM codes are listed below. Diagnosis specificity matters: using an unspecified code when a more specific one is available increases denial risk. Billers who also handle IV therapy intake forms should ensure the intake workflow captures the specific clinical indication at registration.

Always document the clinical rationale for IV iron in the patient’s record, including lab values (serum ferritin, transferrin saturation) and failure or contraindication of oral iron supplementation where applicable. This documentation supports medical necessity reviews and LCD/NCD compliance.

Clinics wanting a structured approach to pre-treatment documentation may benefit from reviewing who can administer IV therapy and what clinical documentation requirements apply to their state. For the most common comorbid diagnosis pairing, see our dedicated guide to ICD-10 code D50.0.

Prior authorization and coverage guidelines by payer for J2916

Prior authorization requirements for J2916 vary significantly by payer. There is no universal rule, and assuming coverage without verification is a common source of claim denials.

Medicare Part B: Generally does not require prior authorization for J2916 in approved indications (iron deficiency anemia, CKD/dialysis). Coverage is governed by applicable Local Coverage Determinations (LCDs). Practices should verify that the indication is within scope of the relevant LCD for their MAC jurisdiction.

Medicaid: Requirements differ by state. North Carolina Medicaid terminated Clinical Policy 1B-3 for J2916 effective April 30, 2018, removing the prior authorization requirement for that code under NC Medicaid as of that date. Louisiana Medicaid’s HCPCS PA List (2Q 2022) listed J2916 without a prior authorization requirement (“No”) for that quarter, though policies may have changed since then.

Kansas Medicaid (KMAP) includes J2916 in its J-code policy bulletin. Billers should consult the current state Medicaid fee schedule and PA list for up-to-date requirements. Practices that handle mobile IV therapy billing across multiple states face compounded variation and need payer-specific PA workflows.

Commercial payers: Most require verification before the first infusion. Common PA triggers include diagnosis type, prior failure of oral iron therapy, serum ferritin thresholds, and specialty of the ordering provider. Use the AAPC Codify HCPCS lookup to cross-reference payer-specific coverage notes before submitting without PA.

Place of service considerations

The setting where J2916 is administered affects reimbursement and billing rules:

• Physician office (POS 11): Bill J2916 under Part B with administration code 96365 (IV infusion, initial). ASP+6% methodology applies.
• Hospital outpatient department (POS 22): The drug and administration are typically bundled under the Outpatient Prospective Payment System (OPPS). The ASP+6% rate does not apply; hospital OPPS rates govern.
• Dialysis facility (POS 65): In most cases, IV iron for ESRD patients is bundled into the dialysis PPS rate. Separate J2916 billing from a dialysis facility is generally not reimbursed under Medicare.
• Patient’s home (POS 12): Home-based infusion follows a separate billing pathway; see HCPCS code S9379 and CPT code 99601 for home infusion billing guidance.

Getting the place of service code wrong on a Part B claim can shift reimbursement from ASP+6% to a bundled rate, or result in outright denial. Infusion suites that see patients across multiple care settings should review prescription management workflows that tie the ordering provider, place of service, and drug documentation together in one record.

NDC crosswalk and related IV iron HCPCS codes

Many payers require the National Drug Code (NDC) on J-code claims, particularly for commercial and Medicaid plans. The NDC identifies the exact product and lot used, adding a layer of claim integrity that payers use to verify the drug matches the J-code billed.

Ferrlecit (sodium ferric gluconate complex in sucrose) is available in a 62.5 mg/5 mL (12.5 mg/mL) single-dose vial. The NDC should be pulled from the vial label at the time of administration and recorded in the patient’s clinical note.

Use the PGM Billing HCPCS lookup tool to cross-reference J2916 against current NDC-to-HCPCS mappings. Clinics that document NDCs at the point of care through their practice management system eliminate the retroactive lookup step entirely. Review how IV therapy billing documentation integrates with practice workflows for practical setup guidance.

J2916 vs. related IV iron J-codes

Several HCPCS codes cover IV iron products. Selecting the wrong code creates a claim denial because each code is tied to a specific drug. The table below compares J2916 with the most commonly confused alternatives.

J1756 (Venofer) is the code most often confused with J2916. Both are sucrose-based IV iron preparations used in similar patient populations, but they are chemically distinct products with different dosing protocols, billing units, and NDCs.

Billing J2916 when Venofer was administered constitutes a coding error. Practices that stock multiple IV iron products should implement a protocol that ties the specific product administered to the correct J-code at point of documentation, applying the same procedure code billing principles across every product in their formulary.

Documentation requirements and claim submission workflow for J2916

A clean J2916 claim requires documentation from three sources: the clinical record, the pharmacy record, and the billing interface. Missing or inconsistent documentation in any of the three is where denials originate.

Required documentation checklist

• Physician order: Written order specifying the drug (Ferrlecit/sodium ferric gluconate), dose in milligrams, route, and frequency.
• Clinical indication: Documented diagnosis with supporting lab values (ferritin, TSAT, hemoglobin) demonstrating medical necessity.
• Administration record: Date, time, milligrams administered, milligrams discarded (if any), administering clinician, and vial lot/NDC.
• Modifier documentation: Clear record of whether full vial was used (supports JZ) or partial vial with wastage (supports JW line).
• Place of service: Accurate setting to determine correct reimbursement pathway.

Practices running HIPAA-compliant billing workflows benefit from having documentation checklists built into their clinical note templates. This keeps the administered dose, NDC, and wastage data in a single structured record rather than scattered across paper logs and spreadsheets.

When submitting on a CMS-1500 form or 837P electronic claim, bill J2916 on one line per dose event. If the JW modifier applies, add a second line for the wasted units. Include the NDC in the required format (11-digit, 5-4-2 format with the appropriate qualifier). Attach the relevant ICD-10-CM diagnosis code(s) in the appropriate diagnosis pointer fields.

Conclusion

J2916 billing errors fall into three predictable categories: wrong unit count, missing or incorrect JW/JZ modifiers, and unsupported ICD-10 diagnosis codes. Each is preventable with the right documentation workflow.

Pabau’s claims management software connects clinical documentation to billing, so dose data flows directly into unit calculations and modifiers are prompted at the point of care. To see how it works for infusion-based practices, book a demo.

Continue your research

Also managing hemodialysis patients on the same iron regimen? CPT code 90935 covers billing for hemodialysis with physician evaluation.

Billing other single-source injectables? HCPCS code J1160 walks through the same unit-conversion and JW/JZ modifier logic for digoxin injection.

Need a standard intake document for infusion patients? Health worksheet templates give billing teams a structured starting point for capturing clinical history.

Frequently asked questions